Answer
It is unknown whether nivolumab passes into human breast milk, and risk to newborns or infants cannot be excluded; a decision must be made whether to discontinue breastfeeding or nivolumab, considering the benefit of breastfeeding for the child and therapy for the woman.
Sources for this answer
- OPDIVO 10 mg/mL concentrate for solution for infusionBristol Myers Squibb Pharmaceuticals limited · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 70Document updated
Sources checked